2010년 전국 72개 병원에서 신생아 호흡곤란증후군의 폐 표면활 성제 치료 결과: 지난 20년간의 비교
Surfactant Replacement Therapy for RDS: a Collaborative Study of 72 Multi-center Trials in Korea (2010) and a Review of Korean Experiences over 20 Years
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
In Korea, pulmonary surfactant (PS) replacement therapy in respiratory distress syndrome (RDS) was started in 1991 since when Surfacten^® was imported from Japan. At the present time, Surfacten^®, Newfactan^®, Curosurf^®, and Infasurf^® are available in Korea. The governmental health insurance covers the expense for multiple dose treatment since 2002 and the early prophylactic treatment (BW: <1,250 g or GP: <30 wks) since 2011. We undertook a multi-institutional collective study to evaluate the outcomes of PS over past 20 years in Korea (Period-I; 1990/91, P-II; 1996, P-III; 2002, and P-IV; 2007, P-V; 2010). There were 60 RDS neonates with PS treatment in P-I (16 hospitals), 1,179 in P-II (64), 1,595 in P-III (62), 1,921 in P-IV (57), and 3,160 in P-V (72). Decreased mortality rate, defined as the percentage of neonates who died within 28 days of birth, was seen between periods, P-V vs P-I, II, III,and IV (mortality rate: 10.1% vs. 40.0%, 30.0%, 18.7%, and 14.3%). We conclude that PS therapy contributed to improve remarkable outcome in RDS neonates over the last 20 years in Korea. However, more efforts should be made to optimize PS therapy for better outcome. Multiple PS doses for relapse and poor response, early prophylactic use, and better supportive care for pre-term infants are mandatory.
Abstract
In Korea, pulmonary surfactant (PS) replacement therapy in respiratory distress syndrome (RDS) was started in 1991 since when Surfacten^® was imported from Japan. At the present time, Surfacten^®, Newfactan^®, Curosurf^®, and Infasurf^® are available in Korea. The governmental health insurance covers the expense for multiple dose treatment since 2002 and the early prophylactic treatment (BW: <1,250 g or GP: <30 wks) since 2011. We undertook a multi-institutional collective study to evaluate the outcomes of PS over past 20 years in Korea (Period-I; 1990/91, P-II; 1996, P-III; 2002, and P-IV; 2007, P-V; 2010). There were 60 RDS neonates with PS treatment in P-I (16 hospitals), 1,179 in P-II (64), 1,595 in P-III (62), 1,921 in P-IV (57), and 3,160 in P-V (72). Decreased mortality rate, defined as the percentage of neonates who died within 28 days of birth, was seen between periods, P-V vs P-I, II, III,and IV (mortality rate: 10.1% vs. 40.0%, 30.0%, 18.7%, and 14.3%). We conclude that PS therapy contributed to improve remarkable outcome in RDS neonates over the last 20 years in Korea. However, more efforts should be made to optimize PS therapy for better outcome. Multiple PS doses for relapse and poor response, early prophylactic use, and better supportive care for pre-term infants are mandatory.
참고문헌 (11)
- Fujiwara T, "Artificial surfactant therapy in hyaline-membrane disease", Lancet, 1, pp.55~59 (1980)
- "Intercontinental Medical Statistics Korea"[URL]
- Namgung R, "Exogenous surfactant replacement therapy of hyaline membrane disease: a controlled clinical trial", J Korean Pediatr Soc, 33, pp.22~35 (1990)
- Park CO, "Surfactant replacement therapy in neonatal respiratory distress syndrome", J Korean Pediatr Soc, 34, pp.1211~1222 (1991)
- Bae CW, "Surfactant replacement therapy in neonates with respiratory distress syndrome: a collective evaluation of trials from 16 hospitals", J Korean Pediatr Soc, 36, pp.244~265 (1993)
- Bae CW, "Surfactant replacement therapy in RDS: a collaborative study of multi-center trials in Korea", J Korean Soc Neonatol, 1, pp.124~135 (1997)
- 배종우, "신생아 호흡곤란 증후군에서 인공 폐 표면활성제 보충요법 제 3보고 : 지난 15년간 한국에서의 치료 결과", Korean Journal of Pediatrics, 47(9), pp.940~948 (2004), 대한소아과학회
- 배종우, "Surfactant Therapy for Neonatal Respiratory Distress Syndrome: A Review of Korean Experiences over 17 Years", Journal of Korean Medical Science, 24(6), pp.1110~1118 (2009), 대한의학회
- 장지영, "Decreasing Trends of Neonatal and Infant Mortality Rates in Korea: Compared with Japan, USA, and OECD Nations", Journal of Korean Medical Science, 26(9), pp.1115~1123 (2011), 대한의학회
- Halliday HL, "Surfactants: past, present and future", J Perinatol, 28(Suppl 1), pp.S47~S56 (2008)
- 김성미, "신생아 호흡곤란증후군에서 인공 폐 표면활성제 조기요법의 중요성과 필요성", 대한신생아학회지, 16(2), pp.101~109 (2009), 대한신생아학회